| Title | Preclinical evaluation of MC1R targeting theranostic pair [155Tb]Tb-crown-αMSH and [161Tb]Tb-crown-αMSH |
| Publication Type | Journal Article |
| Year of Publication | 2024 |
| Authors | Wharton, L, McNeil, SW, Zhang, C, Engudar, G, Van de Voorde, M, Zeisler, J, Koniar, H, Sekar, S, Yuan, Z, Schaffer, P, Radchenko, V, Ooms, M, Kunz, P, Bénard, F, Yang, H |
| Journal | Nuclear Medicine and Biology |
| Volume | 136-137 |
| Abstract | Targeted radionuclide therapy is established as a highly effective strategy for the treatment of metastatic tumors; however, the co-development of suitable imaging companions to therapy remains significant challenge. Theranostic isotopes of terbium (149Tb, 152Tb, 155Tb, 161Tb) have the potential to provide chemically identical radionuclidic pairs, which collectively encompass all modes of nuclear decay relevant to nuclear medicine. Herein, we report the first radiochemistry and preclinical studies involving 155Tb- and 161Tb-labeled crown-αMSH, a small peptide-based bioconjugate suitable for targeting melanoma. |
| DOI | 10.1016/j.nucmedbio.2024.108925 |
